Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic profiling Proteogenomic landscape of multiple myeloma reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma

ABSTRACT: Multiple myeloma is a plasma cell malignancy of the bone marrow. Despite therapeutic advances in multiple myeloma, it remains incurable and better risk stratification as well as new therapies are therefore highly needed. While genetics and gene expression have been extensively studied leading to new insights in disease biology and improved prognostic models, the proteome of multiple myeloma has not been systematically assessed. Here, we provide a comprehensive multi-omic analysis including deep tandem mass tags (TMT)-based quantitative global (phospho)proteomics, RNA sequencing and nanopore DNA sequencing of 138 primary patient-derived plasma cell malignancy samples, including treatment-naive multiple myeloma cases selected for clinical trials, plasma cell leukemia, and the premalignancy MGUS, as well as healthy controls. We found that the (phospho)proteome of malignant plasma cells is highly deregulated as compared to healthy cells and is both defined by chromosomal alterations and extensive post-transcriptional regulation. A protein signature consisting of 8 proteins was identified that is associated with aggressive disease and highly predictive for outcomes in newly diagnosed multiple myeloma. Integration with functional genetics and single-cell sequencing revealed generally and genetic subtype-specific deregulated proteins and pathways in plasma cell malignancies that include novel potential targets for (immuno)therapies. Our study provides a unique resource for investigating biology and new therapeutic approaches in multiple myeloma and associated diseases and highlights the broad implications of proteomic studies in cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE222727 | GEO | 2024/01/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Multiple myeloma

Project description:Multiple myeloma

| PRJNA515992 | ENA

Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma

Project description:Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM remains incurable and in need of guidelines to identify effective personalized treatments. Here, we survey the ex vivo drug and immunotherapy sensitivities across 101 bone marrow (BM) samples from 70 MM patients using multiplexed immunofluorescence, automated microscopy and deep learning-based single-cell phenotyping. Combined with sample-matched genetics, proteotyping, and cytokine profiling, we map the molecular regulatory network of drug sensitivity, implicating the DNA-repair pathway and EYA3 expression in proteasome inhibitor sensitivity, and MHC class II expression in the response to Elotuzumab. Globally, ex vivo drug sensitivity associated with BM microenvironmental signatures reflecting treatment stage, clonality, and inflammation. Furthermore, ex vivo drug sensitivity significantly stratified clinical treatment responses, including to immunotherapy. Taken together, our study provides molecular and actionable insights into diverse treatment strategies for multiple myeloma patients.

2022-03-06 | MSV000088992 | MassIVE

Clonal evolution in multiple myeloma after treatment pressure: heterogenous genomic aberrations and transcriptomic convergence

Project description:Multiple myeloma (MM) is still an incurable plasma cell malignancy that generally responds well to treatment intitially, but eventually becomes refractory. In the present study, genomic and transcriptomic changes were investigated in paired early and late tumor samples of MM patients .

2022-05-01 | GSE179929 | GEO

Gene expression signatures in multiple myeloma

Project description:In the present study, the gene expression profiling was carried out to identify the gene targets affected by miRNAs deregulated in multiple myeloma. A gene expression signature was generated for 45 patients of multiple myeloma as compared to controls (Pooled from 10 Hodgkin's disease samples).

2020-01-24 | GSE125361 | GEO

Expression profiling of microRNAs enriched in small extracellular vesicles isolated from bone marrow plasma of patients with multiple myeloma, extramedullary disease, and plasma cell leukemia

Project description:Multiple myeloma is a plasma cell malignancy characterized by the abnormal increase of monoclonal immunoglobulins. Despite great treatment advances, there are still patients experiencing migration of tumor cells from the bone marrow and progression of the disease into its aggressive forms including extramedullary disease or plasma cell leukemia. Although the exact molecular mechanisms are not known, several studies have confirmed the involvement of small extracellular vesicles-enriched microRNAs in multiple myeloma progression. Thus, we have performed the expression profiling of these molecules in bone marrow plasma of patients with multiple myeloma, extramedullary disease, and plasma cell leukemia using next-generation sequencing with the aim to identify new molecules involved in the disease pathogenesis. In total, 42 microRNAs were wound to be significantly deregulated among analyzed subgroups. The independent validation by RT-qPCR confirmed the elevated levels of miR-155-5p, miR-140-3p, miR-584-5p, miR-191-5p, and miR-143-3p in patients with multiple myeloma compared to extramedullary disease and/or plasma cell leukemia. Subsequent statistical analysis proved several significant correlations between clinical characteristics or flow cytometry parameters of patients and microRNAs’ expression. In addition, low levels of miR 140 3p, miR-191-5p, miR-744-5p, and miR-143-3p were associated with worse overall survival. These results indicate that deregulation of microRNAs could contribute to multiple myeloma progression. Nevertheless, the exact mechanisms have yet to be clarified.

2024-04-30 | GSE262424 | GEO

Circulating miRNAs spectra in plasma of multiple myeloma patients compared with healthy individuals

Project description:MicroRNAs (miRNAs) are a class of small non-coding single-stranded RNAs whose dysregulation of expression plays an important role in cancer development. Circulating miRNAs are novel biomarkers in several cancers. Thus, we explored whether the miRNAs in plasma could be useful clinical biomarkers for multiple myeloma (MM) patients. The expression levels of four miRNAs in plasma were upregulated while eight miRNAs were downregulated in MM patients compared with healthy controls according to microarray. MiRNA microarray was conducted to determine deregulated miRNAs in plasma of 9 MM patients and 7 healthy controls.

2014-01-16 | E-GEOD-54156 | biostudies-arrayexpress

miRNA profiling of multiple myeloma, MGUS, multiple myeloma cell lines and normal plasma cells

Project description:miRNA profiling in multiple myeloma - microRNAs represent a class of noncoding regulators of gene expression implicated in several biological and pathophysiological processes, including cancer. We investigate here their role in multiple myeloma using miChip-arrays interrogating 559 miRNAs in 92 purified myeloma-, MGUS-, normal plasma cell- and myeloma cell line samples. Impact on gene expression is assessed by Affymetrix U133 2.0 DNA-microarrays in 741 samples including two cohorts of 332 and 345 myeloma patients; chromosomal aberrations are assessed by iFISH, survival for 247 and 345 patients undergoing up-front high-dose therapy and autologous stem cell transplantation. Compared to normal plasma cells, 67/559 (12%) miRNAs are differentially expressed with fold changes of 4.6 to -3.1 in myeloma-, 20 (3.6%) in MGUS-samples, and three (0.5%) between MGUS- and myeloma-samples. Expression of miRNAs is associated with biological and pathophysiological parameters, i.e. proliferation, chromosomal aberrations, e.g. t(4;14), tumor mass, and gene expression-based high-risk scores. This holds true for target-gene signatures of regulated mRNAs. miRNA-expression confers prognostic significance for event-free (72/559) and overall survival (69/559), as do respective target-gene signatures. In conclusion, the miRNome of myeloma confers a pattern of small changes of individual miRNAs compared to normal plasma cells impacting on gene expression, biological functions, and survival.

2014-01-09 | E-MTAB-1363 | biostudies-arrayexpress

Multiple Myeloma cells

Project description:Multiple Myeloma cells

| PRJNA800411 | ENA

Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance

Project description:The myeloma cell surface proteome (“surfaceome”) not only determines tumor interaction with the microenvironment but serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to first define surface markers most-enriched on myeloma when compared to B-cell malignancy models, revealing unexpected biological signatures unique to malignant plasma cells. We next integrate our proteomic dataset with existing transcriptome databases, nominating CCR10 and TXNDC11 as possible monotherapeutic targets and CD48 as a promising co-target for increasing avidity of BCMA-directed cellular therapies. We further identify potential biomarkers of resistance to proteasome inhibitors and lenalidomide including changes in CD53, EVI2B, CD10, and CD33. Comparison of short-term treatment with chronic resistance delineates large differences in surface proteome profile under each type of drug exposure. Finally, we develop a miniaturized version of the surface proteomics protocol and present the first surface proteomic profile of a primary plasma cell sample. Our dataset provides a unique resource to advance the biological, therapeutic, and diagnostic understanding of myeloma.

2021-12-10 | GSE160572 | GEO

RNA-seq of Multiple Myeloma

Project description:Purpose: Multiple myeloma is a malignancy of plasma cells. Extensive genetic and transcriptional characterization of myeloma has identified subtypes with prognostic and therapeutic implications. In contrast, relatively little is known about the myeloma epigenome. Experimental Design: CD138+CD38+ myeloma cells were isolated from fresh bone marrow aspirate or the same aspirate after freezing for one to six months. Gene expression and chromatin accessibility were compared between fresh and frozen samples by RNA-seq and ATAC-seq. Chromatin accessible regions were used to identify regulatory RNA expression in over 700 samples from newly diagnosed patients in the MMRF CoMMpass trial (NCT01454297). Results: Gene expression and chromatin accessibility of cryopreserved myeloma recapitulated that of freshly isolated samples. ATAC-seq performed on a series of biobanked specimens identified thousands of chromatin accessible regions with hundreds being highly coordinated with gene expression. Over 4,700 of these chromatin accessible regions were transcribed in newly diagnosed myelomas from the CoMMpass trial. Regulatory element activity alone recapitulated myeloma gene expression subtypes, and in particular myeloma subtypes with IGH translocations were defined by transcription of distal regulatory elements. Moreover, enhancer activity predicted oncogene expression implicating gene regulatory mechanisms in aggressive myeloma. Conclusions: These data demonstrate the feasibility of using biobanked specimens for retrospective studies of the myeloma epigenome and illustrate the unique enhancer landscapes of myeloma subtypes that are coupled to gene expression and disease progression.

2021-03-03 | GSE167968 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data